Characterization of a c-Rel inhibitor that mediates anticancer properties in hematologic malignancies by blocking NF-κB-controlled oxidative stress responses

Cancer Research

Volumn 76, Issue 2, 2016, Pages 377-389

  Shono, Yusuke ^a   Tuckett, Andrea Z ^a   Liou, Hsiou Chi ^b   Doubrovina, Ekaterina ^a   Derenzini, Enrico ^a   Ouk, Samedy ^b   Tsai, Jennifer J ^a   Smith, Odette M ^a   Levy, Emily R ^a   Kreines, Fabiana M ^a   Ziegler, Carly G K ^a   Scallion, Mary I ^a   Doubrovin, Mikhail ^a   Heller, Glenn ^a   Younes, Anas ^a   O'Reilly, Richard J ^a   Van Den Brink, Marcel R M ^a   Zakrzewski, Johannes L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ImmuneTarget Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; C REL INHIBITOR; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IT 603; IT 901; NAPHTHALENETHIOBARBITURATE DERIVATIVE; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; TRANSCRIPTION FACTOR REL;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CELL STIMULATION; CELL STRESS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG HALF LIFE; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LYMPHOMA CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; NONOBESE DIABETIC MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; NF-KAPPA B; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-REL; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84959020681     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2814     Document Type: Article

References (54)

1. Fullard N, Wilson CL, Oakley F. Roles of c-Rel signalling in inflammation and disease. Int J Biochem Cell Biol 2012;44:851-60.
2. Liou HC, Hsia CY. Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 2003;25:767-80.
3. Liou HC, Jin Z, Tumang J, Andjelic S, Smith KA, Liou ML. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 1999;11:361-71.
4. Visekruna A, Volkov A, Steinhoff U. A key role for NF-kappaB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions. Clin Dev Immunol 2012;2012:239368.
5. Yu Y, Wang D, Kaosaard K, Liu C, Fu J, Haarberg K, et al. c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice. Eur J Immunol 2013;43:2327-37.
6. Finn PW, He H, Ma C, Mueller T, Stone JR, Liou HC, et al. Molecular profiling of the role of the NF-kappaB family of transcription factors during alloimmunity. J Leukoc Biol 2002;72:1054-62.
7. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
8. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009;1:a000034.
9. Shono Y, Tuckett AZ, Ouk S, Liou HC, Altan-Bonnet G, Tsai JJ, et al. A smallmolecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity. Cancer Discov 2014;4:578-91.
10. Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012;37:339-50.
11. Ouk S, Liou ML, Liou HC. Direct Rel/NFkB inhibitors: structural basis for mechanism of action. Future Med Chem 2009;1:1683-707.
12. Liou HC. Methods and compositions for targeting c-Rel. United States Patent Application Publication 2010.
13. Liou HC, Sha WC, Scott ML, Baltimore D. Sequential induction of NFkappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994;14:5349-59.
14. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996;88:3230-9.
15. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 2006;12: 1039-47.
16. Petrovic A, Alpdogan O, Willis LM, Eng JM, Greenberg AS, Kappel BJ, et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 2004;103:1542-7.
17. Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005;106:3322-30.
18. Egan LJ, Toruner M. NF-kappaB signaling: pros and cons of altering NFkappaB as a therapeutic approach. Ann N Y Acad Sci 2006;1072:114-22.
19. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 2013;5:1704-13.
20. Available from: http://www.gtexportal.org.
21. Available from: http://www.broadinstitute.org/ccle.
22. Clarke JL, PaoW,WuN,Miller VA, Lassman AB. High doseweekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010;99:283-6.
23. QinW, Tao H, Chen Y, Chen Z,WuN. Sensitive, accurate and simple liquid chromatography-tandem mass spectrometric method for the quantitation of amphotericin B in human or minipig plasma. J Chromatogr Sci 2012;50:636-43.
24. Bista RK, Bruch RF, Covington AM. Infrared spectroscopic study of thermotropic phase behavior of newly developed synthetic biopolymers. Spectrochim Acta A Mol Biomol Spectrosc 2011;81:583-9.
25. Carlsen H, Moskaug J, Fromm SH, Blomhoff R. In vivo imaging of NFkappa B activity. J Immunol 2002;168:41-75.
26. Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR, et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005;106:3293-9.
27. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320:226-30.
28. Staudt LM, Dave S. The biology of human lymphoidmalignancies revealed by gene expression profiling. Adv Immunol 2005;87:163-208.
29. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 2013;13 Suppl 3:41-54; quiz
30. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, et al. Adoptive immunotherapy with unselected or EBVspecific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012;119:2644-56.
31. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
32. RushlowC, Warrior R. The rel family of proteins. Bioessays 1992;14:89-95.
33. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006;124: 823-35.
34. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011;21:103-15.
35. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013;12:931-47.
36. Kardeh S, Ashkani-Esfahani S, Alizadeh AM. Paradoxical action of reactive oxygen species in creation and therapy of cancer. Eur J Pharmacol 2014;735:150-68.
37. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58:262-70.
38. Jastroch M, Divakaruni AS, Mookerjee S, Treberg JR, Brand MD. Mitochondrial proton and electron leaks. Essays Biochem 2010;47:53-67.
39. Brookes PS. Mitochondrial H(+) leak and ROS generation: an odd couple. Free Radic Biol Med 2005;38:12-23.
40. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROSmediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-91.
41. Oussaief L, Ramirez V, Hippocrate A, Arbach H, Cochet C, Proust A, et al. NF-kappaB-mediated modulation of inducible nitric oxide synthase activity controls induction of the Epstein-Barr virus productive cycle by transforming growth factor beta 1. J Virol 2011;85:6502-12.
42. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
43. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
44. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2:58-61.
45. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107:13075-80.
46. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NFkappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-7.
47. Latif T, Chauhan N, Khan R, Moran A, Usmani SZ. Thalidomide and its analogues in the treatment of Multiple Myeloma. Exp Hematol Oncol 2012;1:27.
48. Egan LJ, Eckmann L, Greten FR, Chae S, Li ZW, Myhre GM, et al. IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A 2004;101:2452-7.
49. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006;107: 827-34.
50. Barth TF, Dohner H, Werner CA, Stilgenbauer S, Schlotter M, Pawlita M, et al. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood 1998;91: 4321-30.
51. Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996;87:25-9.
52. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998;92:234-40.
53. Handy DE, Loscalzo J. Redox regulation of mitochondrial function. Antioxid Redox Signal 2012;16:1323-67.
54. Chen W, Balakrishnan K, Kuang Y, Han Y, Fu M, Gandhi V, et al. Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes. J Med Chem 2014;57:4498-510.